Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes.

ABSTRACT:

Background

Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. This study aimed to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, on the obese- and diabetes-related cardiomyopathy.

Methods and results

We used db/db mice and high fat diet-streptozotocin induced diabetic mice to investigate the underlying mechanisms of fenofibrate's beneficial effects on heart function. Fenofibrate reduced fibrosis, and lipid accumulation, and suppressed inflammatory and immunological responses in the heart via TNF signaling. In addition, we investigated the beneficial effects of fenofibrate on

SUBMITTER: Park J 

PROVIDER: S-EPMC11406805 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature